Clinical trials: Systemic Sclerosis-associated Interstitial Lung Disease
Systemic Sclerosis, Scleroderma
Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
By including in this study patients with significant worsening of their lung volumes and / or their DLCO (carbon monoxide diffusing capacity) in the previous year, on the basis of an open retrospective study we recently…
- Conditions
- Systemic Sclerosis, Scleroderma, Interstitial Lung Disease, Lung Fibrosis
- Trial name
- SCLEROCYC (NCT01570764)
- Testing
- Cyclophosphamide
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Diseases, Interstitial
Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
The primary objective is to confirm the incidence of adverse drug reactions (focus on gastrointestinal symptoms including diarrhoea and nausea) to Ofev Capsules seen in clinical trials with real world data generated in patients…
- Trial name
- NCT04325217
- Testing
- Nintedanib
- Where
- Japan
- Volunteers
- 586 people
- Sponsor
- Boehringer Ingelheim
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
- Trial name
- ATHENA-SSc-ILD (NCT05270668)
- Testing
- Tulisokibart, Companion diagnostic ( CDx)
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 154 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated…
- Trial name
- NCT05785624
- Testing
- Vixarelimab
- Where
- 114 sites in United States, Argentina and 17 more
- Volunteers
- 286 people
- Sponsor
- Genentech, Inc.
Scleroderma, Systemic
A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
The main objective is to assess the potential influence of continuous intake of nintedanib on the systemic exposure of ethinylestradiol and levonorgestrel when administered in combination.
- Trial name
- NCT03675581
- Testing
- Microgynon, Nintedanib
- Where
- 10 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).
- Trial name
- NCT03313180
- Testing
- Nintedanib
- Where
- 159 sites in United States, Argentina and 28 more
- Volunteers
- 444 people
- Sponsor
- Boehringer Ingelheim
Interstitial Lung Disease
Pulmonary Care and Research Collaborative Patient Registry
The purpose of this research study is to build and maintain a registry of people with interstitial lung disease (ILD). Medical information collected for this registry may be used to advance ILD and pulmonary research and improve…
- Trial name
- NCT05445817
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Systemic Sclerosis, Interstitial Lung Disease
Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. Interstitial lung disease (ILD) concerns almost 50 % of SSc patients and represents the main cause of…
- Trial name
- LUNGSCLEROCT (NCT05482607)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)
Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease
The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
- Trial name
- NCT03856853
- Testing
- Pirfenidone
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Systemic Sclerosis, Interstitial Lung Disease
Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. In patients with systemic sclerosis, interstitial lung disease (ILD) concerns almost 50 % of patients and…
- Trial name
- SCLEROJAKI (NCT05177471)
- Where
- France
- Sponsor
- Central Hospital, Nancy, France
Chronic Obstructive Pulmonary Disease (COPD), Smoking
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
The purpose of this study is to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- NCT01776398
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
This study was conducted in a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Genakumab injection in the treatment of CTD-ILD including Rheumatoid Arthritis associated Interstitial Lung…
- Conditions
- Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
- Trial name
- NCT06189495
- Testing
- GenSci048
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Interstitial Lung Diseases
Monitoring and Evaluation Study of Project ECHO for ILD
The study will utilize pre-post survey measures to evaluate Project ECHO for ILD with respect to an initial set of practice and clinical outcomes and relies on questionnaire data obtained from providers participating in Project…
- Trial name
- NCT05455437
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Systemic Sclerosis With Lung Involvement, Systemic Sclerosis
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement.
- Conditions
- Systemic Sclerosis With Lung Involvement, Systemic Sclerosis, Interstitial Lung Disease
- Trial name
- SSc-mILD (NCT05785065)
- Testing
- Mycophenolate Mofetil
- Where
- 3 sites in Canada
- Volunteers
- 35 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Lung Diseases, Interstitial, Lung Disease With Systemic Sclerosis
Non-interventional Study Describing Epidemiology, Prognosis and Patient Healthcare Costs in France, 2010-2017
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders, which encompass a wide range of conditions. In some patients with fibrosing ILDs, a progressive phenotype similar to that observed in idiopathic pulmonary…
- Trial name
- PROGRESS (NCT03858842)
- Testing
- epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon